share_log

君聖泰醫藥-B：股東週年大會通告

HIGHTIDE-B: NOTICE OF ANNUAL GENERAL MEETING

Hong Kong Stock Exchange ·  Apr 23 18:25
Summary by Futu AI
君聖泰醫藥-B（股份代號：2511）將於2024年5月16日透過虛擬會議方式舉行股東週年大會，處理包括審核及採納2023年度財務報表、董事會報告及核數師報告等事項。會上將重選劉利平博士為執行董事，朱迅博士及馬立雄先生為非執行董事，並授權董事會釐定董事酬金。此外，將續聘安永會計師事務所為核數師，並授權董事會釐定其酬金。大會亦將考慮授權董事在未來一年內發行不超過已發行股份總數20%的新股份，以及購回不超過已發行股份總數10%的股份。股份過戶登記將於2024年5月9日至5月16日暫停。股東需於2024年5月8日下午四時三十分前遞交過戶文件以出席大會並投票。
君聖泰醫藥-B（股份代號：2511）將於2024年5月16日透過虛擬會議方式舉行股東週年大會，處理包括審核及採納2023年度財務報表、董事會報告及核數師報告等事項。會上將重選劉利平博士為執行董事，朱迅博士及馬立雄先生為非執行董事，並授權董事會釐定董事酬金。此外，將續聘安永會計師事務所為核數師，並授權董事會釐定其酬金。大會亦將考慮授權董事在未來一年內發行不超過已發行股份總數20%的新股份，以及購回不超過已發行股份總數10%的股份。股份過戶登記將於2024年5月9日至5月16日暫停。股東需於2024年5月8日下午四時三十分前遞交過戶文件以出席大會並投票。
JUN SHENG TAI PHARMACEUTICAL-B (STOCK CODE: 2511) WILL HOLD ITS ANNUAL GENERAL MEETING ON 16 MAY 2024 VIA VIRTUAL CONFERENCE TO ADDRESS MATTERS INCLUDING THE AUDIT AND ADOPTION OF THE 2023 FINANCIAL STATEMENTS, BOARD REPORTS AND AUDITOR REPORTS. THE MEETING WILL RE-ELECT DR. LIPING LIU AS EXECUTIVE DIRECTOR, DR. ZHU XUN AND MR. MA LIXIONG AS NON-EXECUTIVE DIRECTORS AND AUTHORIZE THE BOARD TO DETERMINE THE DIRECTORS' REMUNERATION. In addition, EY will be reappointed as an auditor and authorized the Board of Directors to determine their remuneration. The General Meeting will also consider authorizing the directors to issue no more than 20% of the total issued shares over the next year and to repurchase shares not exceeding 10% of the total issued shares. Share transfer registration will be suspended from 9 May 2024 to 16 May 2024. Shareholders are required to submit their registration papers by 4.30pm on 8 May 2024 to attend the General Meeting and vote.
JUN SHENG TAI PHARMACEUTICAL-B (STOCK CODE: 2511) WILL HOLD ITS ANNUAL GENERAL MEETING ON 16 MAY 2024 VIA VIRTUAL CONFERENCE TO ADDRESS MATTERS INCLUDING THE AUDIT AND ADOPTION OF THE 2023 FINANCIAL STATEMENTS, BOARD REPORTS AND AUDITOR REPORTS. THE MEETING WILL RE-ELECT DR. LIPING LIU AS EXECUTIVE DIRECTOR, DR. ZHU XUN AND MR. MA LIXIONG AS NON-EXECUTIVE DIRECTORS AND AUTHORIZE THE BOARD TO DETERMINE THE DIRECTORS' REMUNERATION. In addition, EY will be reappointed as an auditor and authorized the Board of Directors to determine their remuneration. The General Meeting will also consider authorizing the directors to issue no more than 20% of the total issued shares over the next year and to repurchase shares not exceeding 10% of the total issued shares. Share transfer registration will be suspended from 9 May 2024 to 16 May 2024. Shareholders are required to submit their registration papers by 4.30pm on 8 May 2024 to attend the General Meeting and vote.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.